Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/129251
Title: | Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia |
Authors: | Reijnders, Tom D. Y. Laterre, Pierre-François François, Bruno Sánchez García, Miguel van Engelen, Tjitske S. R. Sie, Daoud Scicluna, Brendon P. Ostanin, Dmitry V. Galinsky, Kevin J. Butler, Joe M. Lombardo, Eleuterio van der Poll, Tom |
Authors: | SEPCELL study group |
Keywords: | Pneumonia -- Diagnosis Critical care medicine -- Case studies Immune response Phenotype Genetics |
Issue Date: | 2024 |
Publisher: | BMJ Group |
Citation: | Reijnders, T. D., Laterre, P. F., François, B., García, M. S., van Engelen, T. S., Sie, D., ... & van der Poll, T. (2024). Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia. Thorax, 79(11), 1086-1090. |
Abstract: | Mesenchymal stem cells (MSC) have immune regulatory properties that may ameliorate pathophysiological processes in sepsis. We determined the effect of allogeneic adipose-derived MSCs (Cx611) on the host response during sepsis due to community-acquired bacterial pneumonia (CABP) by measuring 29 plasma biomarkers and blood transcriptomes at six time points in 82 patients randomised to two intravenous infusions of Cx611 or placebo. Cx611 treatment enhanced several endothelial cell and procoagulant response plasma biomarkers, and led to increased expression of pathways related to innate immunity, haemostasis and apoptosis. Cx611 infusion in sepsis due to CABP is associated with broad host response alterations. |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/129251 |
Appears in Collections: | Scholarly Works - FacHScABS |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Effect_of_mesenchymal_stem_cells_on_the_host_response_in_severe_community_acquired_pneumonia.pdf Restricted Access | 1.52 MB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.